Pathogenesis  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
thyroid  ||| S:16 E:24 ||| JJ
eye  ||| S:24 E:28 ||| NN
disease  ||| S:28 E:36 ||| NN
-  ||| S:36 E:38 ||| :
does  ||| S:38 E:43 ||| VBZ
autoimmunity  ||| S:43 E:56 ||| VBN
against  ||| S:56 E:64 ||| IN
the  ||| S:64 E:68 ||| DT
TSH  ||| S:68 E:72 ||| NNP
receptor  ||| S:72 E:81 ||| NN
explain  ||| S:81 E:89 ||| VB
all  ||| S:89 E:93 ||| DT
cases ||| S:93 E:98 ||| NNS
?  ||| S:98 E:100 ||| .
Thyroid  ||| S:100 E:108 ||| RB
associated  ||| S:108 E:119 ||| VBN
ophthalmopathy ||| S:119 E:133 ||| NN
,  ||| S:133 E:135 ||| ,
or  ||| S:135 E:138 ||| CC
thyroid  ||| S:138 E:146 ||| JJ
eye  ||| S:146 E:150 ||| NN
disease  ||| S:150 E:158 ||| NN
( ||| S:158 E:159 ||| -LRB-
TED ||| S:159 E:162 ||| NNP
) ||| S:162 E:163 ||| -RRB-
,  ||| S:163 E:165 ||| ,
is  ||| S:165 E:168 ||| VBZ
a  ||| S:168 E:170 ||| DT
complex  ||| S:170 E:178 ||| JJ
inflammatory  ||| S:178 E:191 ||| JJ
disorder  ||| S:191 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
the  ||| S:203 E:207 ||| DT
eye  ||| S:207 E:211 ||| NN
that ||| S:211 E:215 ||| IN
,  ||| S:215 E:217 ||| ,
as  ||| S:217 E:220 ||| IN
its  ||| S:220 E:224 ||| PRP$
name  ||| S:224 E:229 ||| NN
implies ||| S:229 E:236 ||| VBZ
,  ||| S:236 E:238 ||| ,
is  ||| S:238 E:241 ||| VBZ
usually  ||| S:241 E:249 ||| RB
associated  ||| S:249 E:260 ||| VBN
with  ||| S:260 E:265 ||| IN
thyroid  ||| S:265 E:273 ||| JJ
disease ||| S:273 E:280 ||| NN
.  ||| S:280 E:282 ||| .
Clinical  ||| S:282 E:291 ||| JJ
observation  ||| S:291 E:303 ||| NN
supports  ||| S:303 E:312 ||| VBZ
the  ||| S:312 E:316 ||| DT
existence  ||| S:316 E:326 ||| NN
of  ||| S:326 E:329 ||| IN
three  ||| S:329 E:335 ||| CD
main  ||| S:335 E:340 ||| JJ
TED  ||| S:340 E:344 ||| NNP
subtypes ||| S:344 E:352 ||| NN
,  ||| S:352 E:354 ||| ,
namely  ||| S:354 E:361 ||| RB
ocular  ||| S:361 E:368 ||| JJ
myopathy ||| S:368 E:376 ||| NN
,  ||| S:376 E:378 ||| ,
congestive  ||| S:378 E:389 ||| JJ
myopathy ||| S:389 E:397 ||| NN
,  ||| S:397 E:399 ||| ,
and  ||| S:399 E:403 ||| CC
mixed  ||| S:403 E:409 ||| JJ
congestive  ||| S:409 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
myopathic  ||| S:424 E:434 ||| JJ
ophthalmopathy ||| S:434 E:448 ||| NN
.  ||| S:448 E:450 ||| .
Although  ||| S:450 E:459 ||| IN
the  ||| S:459 E:463 ||| DT
precise  ||| S:463 E:471 ||| JJ
pathophysiology  ||| S:471 E:487 ||| NN
of  ||| S:487 E:490 ||| IN
TED  ||| S:490 E:494 ||| NNP
remains  ||| S:494 E:502 ||| VBZ
unclear ||| S:502 E:509 ||| JJ
,  ||| S:509 E:511 ||| ,
it  ||| S:511 E:514 ||| PRP
is  ||| S:514 E:517 ||| VBZ
likely  ||| S:517 E:524 ||| JJ
to  ||| S:524 E:527 ||| TO
reflect  ||| S:527 E:535 ||| VB
an  ||| S:535 E:538 ||| DT
autoimmune  ||| S:538 E:549 ||| JJ
reaction  ||| S:549 E:558 ||| NN
involving  ||| S:558 E:568 ||| VBG
sensitised  ||| S:568 E:579 ||| JJ
T  ||| S:579 E:581 ||| NN
lymphocytes  ||| S:581 E:593 ||| NNS
and  ||| S:593 E:597 ||| CC
autoantibodies  ||| S:597 E:612 ||| VB
directed  ||| S:612 E:621 ||| VBN
against  ||| S:621 E:629 ||| IN
a  ||| S:629 E:631 ||| DT
specific  ||| S:631 E:640 ||| JJ
orbital  ||| S:640 E:648 ||| NN
or  ||| S:648 E:651 ||| CC
thyroid-and-orbital  ||| S:651 E:671 ||| JJ
shared  ||| S:671 E:678 ||| JJ
antigen ||| S:678 E:685 ||| NN
( ||| S:685 E:686 ||| -LRB-
s ||| S:686 E:687 ||| LS
) ||| S:687 E:688 ||| -RRB-
.  ||| S:688 E:690 ||| .
One  ||| S:690 E:694 ||| CD
well-studied  ||| S:694 E:707 ||| JJ
candidate  ||| S:707 E:717 ||| NN
in  ||| S:717 E:720 ||| IN
this  ||| S:720 E:725 ||| DT
immune  ||| S:725 E:732 ||| JJ
reaction  ||| S:732 E:741 ||| NN
is  ||| S:741 E:744 ||| VBZ
the  ||| S:744 E:748 ||| DT
thyroid-stimulating  ||| S:748 E:768 ||| JJ
hormone  ||| S:768 E:776 ||| NN
receptor  ||| S:776 E:785 ||| NN
( ||| S:785 E:786 ||| -LRB-
TSHR ||| S:786 E:790 ||| NNP
) ||| S:790 E:791 ||| -RRB-
,  ||| S:791 E:793 ||| ,
which  ||| S:793 E:799 ||| WDT
is  ||| S:799 E:802 ||| VBZ
also  ||| S:802 E:807 ||| RB
expressed  ||| S:807 E:817 ||| VBN
in  ||| S:817 E:820 ||| IN
the  ||| S:820 E:824 ||| DT
orbital  ||| S:824 E:832 ||| JJ
fibroblast  ||| S:832 E:843 ||| NN
and  ||| S:843 E:847 ||| CC
preadipocyte ||| S:847 E:859 ||| NN
.  ||| S:859 E:861 ||| .
Most  ||| S:861 E:866 ||| JJS
patients  ||| S:866 E:875 ||| NNS
with  ||| S:875 E:880 ||| IN
ophthalmopathy  ||| S:880 E:895 ||| NNS
have  ||| S:895 E:900 ||| VBP
associated  ||| S:900 E:911 ||| VBN
Graves ||| S:911 E:917 ||| NNP
'  ||| S:917 E:919 ||| POS
disease ||| S:919 E:926 ||| NN
,  ||| S:926 E:928 ||| ,
10 ||| S:928 E:930 ||| CD
%  ||| S:930 E:932 ||| NN
have  ||| S:932 E:937 ||| VBP
Hashimoto ||| S:937 E:946 ||| NNP
's  ||| S:946 E:949 ||| POS
thyroiditis  ||| S:949 E:961 ||| NN
in  ||| S:961 E:964 ||| IN
which  ||| S:964 E:970 ||| WDT
the  ||| S:970 E:974 ||| DT
eye  ||| S:974 E:978 ||| NN
changes  ||| S:978 E:986 ||| NNS
are  ||| S:986 E:990 ||| VBP
often  ||| S:990 E:996 ||| RB
mild  ||| S:996 E:1001 ||| JJ
and  ||| S:1001 E:1005 ||| CC
expressed  ||| S:1005 E:1015 ||| VBD
mainly  ||| S:1015 E:1022 ||| RB
as  ||| S:1022 E:1025 ||| IN
upper  ||| S:1025 E:1031 ||| JJ
eyelid  ||| S:1031 E:1038 ||| JJ
retraction  ||| S:1038 E:1049 ||| NNS
( ||| S:1049 E:1050 ||| -LRB-
UER ||| S:1050 E:1053 ||| NNP
) ||| S:1053 E:1054 ||| -RRB-
,  ||| S:1054 E:1056 ||| ,
and  ||| S:1056 E:1060 ||| CC
10 ||| S:1060 E:1062 ||| CD
%  ||| S:1062 E:1064 ||| NN
have  ||| S:1064 E:1069 ||| VBP
no  ||| S:1069 E:1072 ||| DT
apparent  ||| S:1072 E:1081 ||| JJ
associated  ||| S:1081 E:1092 ||| JJ
thyroid  ||| S:1092 E:1100 ||| JJ
disease  ||| S:1100 E:1108 ||| NN
-  ||| S:1108 E:1110 ||| :
so-called  ||| S:1110 E:1120 ||| JJ
euthyroid  ||| S:1120 E:1130 ||| JJ
Graves ||| S:1130 E:1136 ||| NNP
'  ||| S:1136 E:1138 ||| POS
disease ||| S:1138 E:1145 ||| NN
.  ||| S:1145 E:1147 ||| .
Ophthalmopathy  ||| S:1147 E:1162 ||| NNP
can  ||| S:1162 E:1166 ||| MD
also  ||| S:1166 E:1171 ||| RB
occur  ||| S:1171 E:1177 ||| VB
in  ||| S:1177 E:1180 ||| IN
some  ||| S:1180 E:1185 ||| DT
patients  ||| S:1185 E:1194 ||| NNS
with  ||| S:1194 E:1199 ||| IN
transient  ||| S:1199 E:1209 ||| JJ
thyroiditis ||| S:1209 E:1220 ||| NN
,  ||| S:1220 E:1222 ||| ,
thyroid  ||| S:1222 E:1230 ||| JJ
cancer ||| S:1230 E:1236 ||| NN
,  ||| S:1236 E:1238 ||| ,
and  ||| S:1238 E:1242 ||| CC
Graves ||| S:1242 E:1248 ||| NNP
'  ||| S:1248 E:1250 ||| POS
disease  ||| S:1250 E:1258 ||| NN
many  ||| S:1258 E:1263 ||| JJ
years  ||| S:1263 E:1269 ||| NNS
after  ||| S:1269 E:1275 ||| IN
treatment  ||| S:1275 E:1285 ||| NN
of  ||| S:1285 E:1288 ||| IN
the  ||| S:1288 E:1292 ||| DT
hyperthyroidism  ||| S:1292 E:1308 ||| NN
-  ||| S:1308 E:1310 ||| :
situations  ||| S:1310 E:1321 ||| NNS
where  ||| S:1321 E:1327 ||| WRB
TSHR  ||| S:1327 E:1332 ||| NNP
antibodies  ||| S:1332 E:1343 ||| NNS
are  ||| S:1343 E:1347 ||| VBP
not  ||| S:1347 E:1351 ||| RB
expected  ||| S:1351 E:1360 ||| VBN
to  ||| S:1360 E:1363 ||| TO
be  ||| S:1363 E:1366 ||| VB
present ||| S:1366 E:1373 ||| JJ
,  ||| S:1373 E:1375 ||| ,
suggesting  ||| S:1375 E:1386 ||| VBG
that  ||| S:1386 E:1391 ||| IN
the  ||| S:1391 E:1395 ||| DT
relationship  ||| S:1395 E:1408 ||| NN
between  ||| S:1408 E:1416 ||| IN
TSHR  ||| S:1416 E:1421 ||| NNP
antibodies  ||| S:1421 E:1432 ||| NNS
and  ||| S:1432 E:1436 ||| CC
the  ||| S:1436 E:1440 ||| DT
eye  ||| S:1440 E:1444 ||| NN
disorder  ||| S:1444 E:1453 ||| NN
has  ||| S:1453 E:1457 ||| VBZ
not  ||| S:1457 E:1461 ||| RB
been  ||| S:1461 E:1466 ||| VBN
established  ||| S:1466 E:1478 ||| VBN
for  ||| S:1478 E:1482 ||| IN
all  ||| S:1482 E:1486 ||| DT
cases ||| S:1486 E:1491 ||| NNS
.  ||| S:1491 E:1493 ||| .
In  ||| S:1493 E:1496 ||| IN
our  ||| S:1496 E:1500 ||| PRP$
studies  ||| S:1500 E:1508 ||| NNS
of  ||| S:1508 E:1511 ||| IN
TED  ||| S:1511 E:1515 ||| NNP
we  ||| S:1515 E:1518 ||| PRP
have  ||| S:1518 E:1523 ||| VBP
investigated  ||| S:1523 E:1536 ||| VBN
the  ||| S:1536 E:1540 ||| DT
nature  ||| S:1540 E:1547 ||| NN
and  ||| S:1547 E:1551 ||| CC
significance  ||| S:1551 E:1564 ||| NN
of  ||| S:1564 E:1567 ||| IN
antibodies  ||| S:1567 E:1578 ||| NNS
targeting  ||| S:1578 E:1588 ||| VBG
other  ||| S:1588 E:1594 ||| JJ
eye  ||| S:1594 E:1598 ||| NN
muscle  ||| S:1598 E:1605 ||| NN
and  ||| S:1605 E:1609 ||| CC
orbital  ||| S:1609 E:1617 ||| JJ
connective  ||| S:1617 E:1628 ||| JJ
tissue  ||| S:1628 E:1635 ||| NN
( ||| S:1635 E:1636 ||| -LRB-
OCT ||| S:1636 E:1639 ||| NNP
)  ||| S:1639 E:1641 ||| -RRB-
antigens ||| S:1641 E:1649 ||| NN
,  ||| S:1649 E:1651 ||| ,
in  ||| S:1651 E:1654 ||| IN
particular  ||| S:1654 E:1665 ||| JJ
the  ||| S:1665 E:1669 ||| DT
calcium  ||| S:1669 E:1677 ||| FW
binding  ||| S:1677 E:1685 ||| FW
protein  ||| S:1685 E:1693 ||| FW
calsequestrin  ||| S:1693 E:1707 ||| FW
( ||| S:1707 E:1708 ||| -LRB-
CASQ1 ||| S:1708 E:1713 ||| NNP
)  ||| S:1713 E:1715 ||| -RRB-
and  ||| S:1715 E:1719 ||| CC
the  ||| S:1719 E:1723 ||| DT
orbital  ||| S:1723 E:1731 ||| FW
fibroblast  ||| S:1731 E:1742 ||| FW
membrane  ||| S:1742 E:1751 ||| FW
antigen  ||| S:1751 E:1759 ||| FW
collagen  ||| S:1759 E:1768 ||| FW
XIII ||| S:1768 E:1772 ||| FW
.  ||| S:1772 E:1774 ||| .
Our  ||| S:1774 E:1778 ||| PRP$
working  ||| S:1778 E:1786 ||| JJ
hypotheses  ||| S:1786 E:1797 ||| NN
for  ||| S:1797 E:1801 ||| IN
the  ||| S:1801 E:1805 ||| DT
pathogenesis  ||| S:1805 E:1818 ||| NN
of  ||| S:1818 E:1821 ||| IN
TED  ||| S:1821 E:1825 ||| NNP
are ||| S:1825 E:1828 ||| VBP
:  ||| S:1828 E:1830 ||| :
i ||| S:1830 E:1831 ||| FW
)  ||| S:1831 E:1833 ||| -RRB-
the  ||| S:1833 E:1837 ||| DT
initial  ||| S:1837 E:1845 ||| JJ
reaction  ||| S:1845 E:1854 ||| NN
in  ||| S:1854 E:1857 ||| IN
the  ||| S:1857 E:1861 ||| DT
orbit  ||| S:1861 E:1867 ||| NN
is  ||| S:1867 E:1870 ||| VBZ
antibody  ||| S:1870 E:1879 ||| NN
and  ||| S:1879 E:1883 ||| CC
T  ||| S:1883 E:1885 ||| NN
lymphocyte  ||| S:1885 E:1896 ||| VBZ
targeting  ||| S:1896 E:1906 ||| VBG
of  ||| S:1906 E:1909 ||| IN
the  ||| S:1909 E:1913 ||| DT
TSHR  ||| S:1913 E:1918 ||| NNP
in  ||| S:1918 E:1921 ||| IN
the  ||| S:1921 E:1925 ||| DT
OCT  ||| S:1925 E:1929 ||| NNP
compartment ||| S:1929 E:1940 ||| NN
,  ||| S:1940 E:1942 ||| ,
and  ||| S:1942 E:1946 ||| CC
ii ||| S:1946 E:1948 ||| CD
)  ||| S:1948 E:1950 ||| -RRB-
the  ||| S:1950 E:1954 ||| DT
associated  ||| S:1954 E:1965 ||| JJ
extra  ||| S:1965 E:1971 ||| JJ
ocular  ||| S:1971 E:1978 ||| NN
and  ||| S:1978 E:1982 ||| CC
upper  ||| S:1982 E:1988 ||| JJ
eyelid  ||| S:1988 E:1995 ||| JJ
muscle  ||| S:1995 E:2002 ||| NN
inflammation  ||| S:2002 E:2015 ||| NN
reflects  ||| S:2015 E:2024 ||| VBZ
either  ||| S:2024 E:2031 ||| DT
autoimmunity  ||| S:2031 E:2044 ||| NN
against  ||| S:2044 E:2052 ||| IN
primary  ||| S:2052 E:2060 ||| JJ
skeletal  ||| S:2060 E:2069 ||| JJ
muscle  ||| S:2069 E:2076 ||| NN
antigens  ||| S:2076 E:2085 ||| VBZ
such  ||| S:2085 E:2090 ||| JJ
as  ||| S:2090 E:2093 ||| IN
CASQ1  ||| S:2093 E:2099 ||| NNP
or  ||| S:2099 E:2102 ||| CC
a  ||| S:2102 E:2104 ||| DT
secondary ||| S:2104 E:2113 ||| JJ
,  ||| S:2113 E:2115 ||| ,
non  ||| S:2115 E:2119 ||| JJ
specific  ||| S:2119 E:2128 ||| JJ
effect  ||| S:2128 E:2135 ||| NN
of  ||| S:2135 E:2138 ||| IN
the  ||| S:2138 E:2142 ||| DT
OCT  ||| S:2142 E:2146 ||| NNP
reactions  ||| S:2146 E:2156 ||| NNS
as  ||| S:2156 E:2159 ||| RB
proposed  ||| S:2159 E:2168 ||| VBN
by  ||| S:2168 E:2171 ||| IN
the  ||| S:2171 E:2175 ||| DT
main  ||| S:2175 E:2180 ||| JJ
proponents  ||| S:2180 E:2191 ||| NNS
of  ||| S:2191 E:2194 ||| IN
the  ||| S:2194 E:2198 ||| DT
TSHR  ||| S:2198 E:2203 ||| NNP
hypothesis ||| S:2203 E:2213 ||| NN
.  ||| S:2213 E:2215 ||| .
Here ||| S:2215 E:2219 ||| RB
,  ||| S:2219 E:2221 ||| ,
we  ||| S:2221 E:2224 ||| PRP
review  ||| S:2224 E:2231 ||| VB
the  ||| S:2231 E:2235 ||| DT
evidence  ||| S:2235 E:2244 ||| NN
that  ||| S:2244 E:2249 ||| IN
autoimmunity  ||| S:2249 E:2262 ||| NN
against  ||| S:2262 E:2270 ||| IN
the  ||| S:2270 E:2274 ||| DT
TSHR  ||| S:2274 E:2279 ||| NNP
expressed  ||| S:2279 E:2289 ||| VBD
in  ||| S:2289 E:2292 ||| IN
the  ||| S:2292 E:2296 ||| DT
orbit  ||| S:2296 E:2302 ||| NN
can  ||| S:2302 E:2306 ||| MD
be  ||| S:2306 E:2309 ||| VB
implicated  ||| S:2309 E:2320 ||| VBN
in  ||| S:2320 E:2323 ||| IN
the  ||| S:2323 E:2327 ||| DT
development  ||| S:2327 E:2339 ||| NN
of  ||| S:2339 E:2342 ||| IN
all  ||| S:2342 E:2346 ||| DT
cases  ||| S:2346 E:2352 ||| NNS
of  ||| S:2352 E:2355 ||| IN
TED ||| S:2355 E:2358 ||| NNP
.  ||| S:2358 E:2360 ||| .
Although  ||| S:2360 E:2369 ||| IN
there  ||| S:2369 E:2375 ||| EX
is  ||| S:2375 E:2378 ||| VBZ
a  ||| S:2378 E:2380 ||| DT
close  ||| S:2380 E:2386 ||| JJ
general  ||| S:2386 E:2394 ||| JJ
correlation  ||| S:2394 E:2406 ||| NN
between  ||| S:2406 E:2414 ||| IN
ophthalmopathy  ||| S:2414 E:2429 ||| NN
and  ||| S:2429 E:2433 ||| CC
TSHR  ||| S:2433 E:2438 ||| NNP
antibodies  ||| S:2438 E:2449 ||| VBD
there  ||| S:2449 E:2455 ||| EX
are  ||| S:2455 E:2459 ||| VBP
many  ||| S:2459 E:2464 ||| JJ
exceptions ||| S:2464 E:2474 ||| NNS
,  ||| S:2474 E:2476 ||| ,
suggesting  ||| S:2476 E:2487 ||| VBG
that  ||| S:2487 E:2492 ||| IN
the  ||| S:2492 E:2496 ||| DT
continued  ||| S:2496 E:2506 ||| JJ
study  ||| S:2506 E:2512 ||| NN
of  ||| S:2512 E:2515 ||| IN
the  ||| S:2515 E:2519 ||| DT
possible  ||| S:2519 E:2528 ||| JJ
role  ||| S:2528 E:2533 ||| NN
of  ||| S:2533 E:2536 ||| IN
autoimmunity  ||| S:2536 E:2549 ||| NN
against  ||| S:2549 E:2557 ||| IN
calsequestrin  ||| S:2557 E:2571 ||| NN
and  ||| S:2571 E:2575 ||| CC
collagen  ||| S:2575 E:2584 ||| JJ
XIII  ||| S:2584 E:2589 ||| NNP
is  ||| S:2589 E:2592 ||| VBZ
justified ||| S:2592 E:2601 ||| VBN
.  ||| S:2601 E:2603 ||| .
